4-乙炔基-2-甲基-1-硝基苯 | 187869-73-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙炔基-2-甲基-1-硝基苯
• 英文名称: methyl-4-ethynylnitrobenzene
• 英文别名: 4-Ethynyl-2-methyl-1-nitrobenzene
• CAS: 187869-73-4
• 化学式: C₉H₇NO₂
• mdl: MFCD11041431
• 分子量: 161.16
• InChiKey: GCRZVQMEJMEFFN-UHFFFAOYSA-N

物化性质

• 沸点：
  265.7±33.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-乙炔基-2-甲基-1-硝基苯 在 copper(l) iodide 、 铁粉 、 氯化铵 、 caesium carbonate 、 三乙胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 1-(5-(tert-butyl)isoxazol-3-yl)-3-(2-methyl-4-(1-(4-(2-morpholinoethoxy)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)urea
  参考文献：
  名称：

  Identification and Development of 1,4-Diaryl-1,2,3-triazolo-Based Ureas as Novel FLT3 Inhibitors

  摘要：

  A class were of 1,4-diaryl-1,2,3-triazolo-based ureas were synthesized and developed as novel FLT3 inhibitors. The representative compound 28 strongly inhibited FLT3-ITD kinase (IC50 = 32.8 nM) and isogenic BaF3-FLT3-ITD cell (GI(50) = 0.6 nM). It exhibited potent inhibition against FLT3-ITD positive MV4-11 (GI(50) = 3.0 nM) and MOLM-13 (GI(50) = 5.9 nM) cell lines and high selectivity over FLT3-WT cell lines. It also displayed good pharmacokinetics properties and demonstrated promising oral in vivo efficacy in a MV4-11 cell xenografted mouse model. It might be a potent lead compound for further development to treat FLT3-ITD driven acute myloid leukemia.

  DOI：

  10.1021/acsmedchemlett.0c00216

文献信息

• Synthetic, structural, electrochemical and electronic characterisation of heterobimetallic bis(acetylide) ferrocene complexes
  作者：Michael C. B. Colbert、Jack Lewis、Nicholas J. Long、Paul R. Raithby、Andrew J. P. White、David J. Williams

  DOI：10.1039/a605177d

  日期：——

  A series of novel heterobimetallic bis(acetylide) ferrocene complexes featuring a bis[1,2-bis(diphenylphosphino)methane]ruthenium centre and seven variously substituted aromatic acetylene ligands have been synthesised and characterised. The crystal structure of trans-[Ru(dppm) 2 CC(C 5 H 4 )Fe(C 5 H 5 )} 2 ] shows the ruthenium centre in a distorted-octahedral environment bound to two ferrocene units in a linear fashion by ‘rigid-rod’-like acetylene linkages. The conformation is stabilised by strong intramolecular CH· · ·π(CC) interactions. Electrochemical studies showed that incorporation of donor-substituted aromatic acetylide ligands causes a cathodic shift in the Ru II/III redox potential. Conversely, an anodic shift is observed when electron-withdrawing substituents are present in the acetylide systems. Electronic spectral measurements indicated that the systems belong to the Robin and Day ‘Class II’ mixed-valence species and suggest that greater electronic interaction occurs in the bis(acetylide) complexes than in the corresponding monoacetylide chloro-complex.

  我们合成并表征了一系列新型杂多金属双(乙炔)二茂铁配合物，这些配合物以双[1,2-双(二苯基膦)甲烷]钌中心和七个不同取代的芳香族乙炔配体为特征。反式-[Ru(dppm) 2 CC(C 5 H 4 )Fe(C 5 H 5 )} 2 ]的晶体结构显示，钌中心处于扭曲的八面体环境中，通过 "刚性杆 "状的乙炔连接与两个二茂铁单元线性结合。电化学研究表明，加入供体取代的芳香族乙酰配体会导致 Ru II/III 氧化还原电位发生阴极移动。相反，当乙酰化体系中存在抽电子取代基时，则会出现阳极移动。电子光谱测量结果表明，这些体系属于罗宾和戴的 "第二类 "混价物种，并表明双（乙酰化）络合物比相应的单乙酰化氯络合物发生了更大的电子相互作用。
• Identification and Development of 1,4-Diaryl-1,2,3-triazolo-Based Ureas as Novel FLT3 Inhibitors
  作者：Jisheng Liu、Yuting Wang、Chen Chen、Zhengchao Tu、Sihua Zhu、Fengtao Zhou、Hongfei Si、Canhui Zheng、Zhang Zhang、Qian Cai

  DOI：10.1021/acsmedchemlett.0c00216

  日期：2020.8.13

  A class were of 1,4-diaryl-1,2,3-triazolo-based ureas were synthesized and developed as novel FLT3 inhibitors. The representative compound 28 strongly inhibited FLT3-ITD kinase (IC50 = 32.8 nM) and isogenic BaF3-FLT3-ITD cell (GI(50) = 0.6 nM). It exhibited potent inhibition against FLT3-ITD positive MV4-11 (GI(50) = 3.0 nM) and MOLM-13 (GI(50) = 5.9 nM) cell lines and high selectivity over FLT3-WT cell lines. It also displayed good pharmacokinetics properties and demonstrated promising oral in vivo efficacy in a MV4-11 cell xenografted mouse model. It might be a potent lead compound for further development to treat FLT3-ITD driven acute myloid leukemia.